Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088 --long-lasting improvement of food preference and body weight loss.

Larsen AT, Sonne N, Andreassen KV, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2020 Feb 18. pii: jpet.119.263400. doi: 10.1124/jpet.119.263400. [Epub ahead of print]

2.

The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.

Sonne N, Larsen AT, Andreassen KV, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2020 Apr;373(1):92-102. doi: 10.1124/jpet.119.263723. Epub 2020 Jan 28.

PMID:
31992608
3.

A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model.

Katri A, Dąbrowska A, Löfvall H, Karsdal MA, Andreassen KV, Thudium CS, Henriksen K.

Osteoarthritis Cartilage. 2019 Sep;27(9):1339-1346. doi: 10.1016/j.joca.2019.05.016. Epub 2019 Jun 5.

4.

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.

Larsen AT, Sonne N, Andreassen KV, Gehring K, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2019 Jul;370(1):35-43. doi: 10.1124/jpet.119.257576. Epub 2019 Apr 26.

PMID:
31028106
5.

Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model.

Katri A, Dąbrowska A, Löfvall H, Ding M, Karsdal MA, Andreassen KV, Thudium CS, Henriksen K.

Arthritis Res Ther. 2019 Feb 22;21(1):68. doi: 10.1186/s13075-019-1819-9.

6.

The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes.

Hjuler ST, Gydesen S, Andreassen KV, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2017 Jul;362(1):24-30. doi: 10.1124/jpet.117.241281. Epub 2017 Apr 24.

PMID:
28438778
7.

Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.

Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K.

Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E598-E607. doi: 10.1152/ajpendo.00419.2016. Epub 2017 Mar 14.

8.

A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.

Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, Karsdal MA, Henriksen K.

Br J Pharmacol. 2017 Apr;174(7):591-602. doi: 10.1111/bph.13723. Epub 2017 Feb 15.

9.

The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity.

Hjuler ST, Gydesen S, Andreassen KV, Pedersen SL, Hellgren LI, Karsdal MA, Henriksen K.

Obesity (Silver Spring). 2016 Aug;24(8):1712-22. doi: 10.1002/oby.21563. Epub 2016 Jun 14.

10.

KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.

Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K.

Am J Physiol Endocrinol Metab. 2016 May 15;310(10):E821-7. doi: 10.1152/ajpendo.00514.2015. Epub 2016 Feb 23.

11.

KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration.

Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K.

Eur J Pharmacol. 2015 Sep 5;762:229-38. doi: 10.1016/j.ejphar.2015.05.051. Epub 2015 May 28.

PMID:
26027795
12.

Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats.

Feigh M, Hjuler ST, Andreassen KV, Gydesen S, Ottosen I, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA, Henriksen K.

Eur J Pharmacol. 2014 Aug 15;737:91-6. doi: 10.1016/j.ejphar.2014.05.016. Epub 2014 May 22.

PMID:
24858364
13.

A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.

Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA, Henriksen K.

Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E24-33. doi: 10.1152/ajpendo.00121.2014. Epub 2014 May 6.

14.

Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias.

Andreassen KV, Hjuler ST, Furness SG, Sexton PM, Christopoulos A, Nosjean O, Karsdal MA, Henriksen K.

PLoS One. 2014 Mar 18;9(3):e92042. doi: 10.1371/journal.pone.0092042. eCollection 2014.

15.

Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats.

Feigh M, Andreassen KV, Hjuler ST, Nielsen RH, Christiansen C, Henriksen K, Karsdal MA.

Menopause. 2013 Jul;20(7):785-94. doi: 10.1097/GME.0b013e31827c58ab.

PMID:
23793169
16.

Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.

Neutzsky-Wulff AV, Andreassen KV, Hjuler ST, Feigh M, Bay-Jensen AC, Zheng Q, Henriksen K, Karsdal MA.

J Transl Med. 2012 Oct 30;10:214. doi: 10.1186/1479-5876-10-214.

17.

The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage.

Chen-An P, Andreassen KV, Henriksen K, Li Y, Karsdal MA, Bay-Jensen AC.

PLoS One. 2012;7(6):e40081. doi: 10.1371/journal.pone.0040081. Epub 2012 Jun 29.

18.

A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts.

Henriksen K, Andreassen KV, Thudium CS, Gudmann KN, Moscatelli I, Crüger-Hansen CE, Schulz AS, Dziegiel MH, Richter J, Karsdal MA, Neutzsky-Wulff AV.

Bone. 2012 Sep;51(3):353-61. doi: 10.1016/j.bone.2012.06.007. Epub 2012 Jun 19.

PMID:
22722081
19.

Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.

Feigh M, Andreassen KV, Neutzsky-Wulff AV, Petersen ST, Hansen C, Bay-Jensen AC, Henriksen JE, Beck-Nielsen H, Christiansen C, Henriksen K, Karsdal MA.

Br J Pharmacol. 2012 Sep;167(1):151-63. doi: 10.1111/j.1476-5381.2012.01979.x.

20.

Investigation of chondrocyte hypertrophy and cartilage calcification in a full-depth articular cartilage explants model.

Chen-An P, Andreassen KV, Henriksen K, Karsdal MA, Bay-Jensen AC.

Rheumatol Int. 2013 Feb;33(2):401-11. doi: 10.1007/s00296-012-2368-6. Epub 2012 Mar 28.

PMID:
22453523
21.

Glucocorticoids exert context-dependent effects on cells of the joint in vitro.

Madsen SH, Andreassen KV, Christensen ST, Karsdal MA, Sverdrup FM, Bay-Jensen AC, Henriksen K.

Steroids. 2011 Dec 11;76(13):1474-82. doi: 10.1016/j.steroids.2011.07.018. Epub 2011 Aug 10.

PMID:
21855558
22.

A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.

Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA.

Diabetes Obes Metab. 2011 Oct;13(10):911-20. doi: 10.1111/j.1463-1326.2011.01425.x.

PMID:
21615667

Supplemental Content

Loading ...
Support Center